http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2026, Vol. 35 ›› Issue (1): 54-70.DOI: 10.5246/jcps.2026.01.004

• Original articles • Previous Articles     Next Articles

Preparation and evaluation of cefditoren bioadhesive sustained-release dry suspension in vitro and in vivo studies

Yuanrong Xin1, Chi Zhang1, Jintong Dai1, Kailun Yang3, Haibing He4,*(), Hongfei Liu1,2,*()   

  1. 1 College of Pharmacy, Jiangsu University, Zhenjiang 212013, Jiangsu, China
    2 Jiangmen Hongxiao Biomedical Co., Ltd, Jiangmen 529000, Guangdong, China
    3 Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
    4 Jiangsu Haizhihong Biomedical Co., Ltd, Nantong 226001, Jiangsu, China
  • Received:2025-09-25 Revised:2025-10-21 Accepted:2025-11-06 Online:2026-01-31 Published:2026-01-31
  • Contact: Haibing He, Hongfei Liu
  • Supported by:
    The 2023 Nantong Jianghai Talents Project, 2023 Nantong Social Livelihood Science and Technology Plan, 2022 New Drugs and Platform Enhancement Project of the Yangtze Delta Drug Advanced Research Institute, Wuyi University Scientific Research Project (Grant No. 2023AL001), and the Innovation and Entrepreneurship Project for Returned Overseas Students in Jiangmen.

Abstract:

In the present study, cefditoren sodium (CT-Na), the sodium salt form of cefditoren (CT), was selected as the model compound, and cholestyramine resin was employed as the drug carrier to formulate CT-Na-resin complexes. The interaction mechanism between CT-Na and cholestyramine resin was elucidated using scanning electron microscopy (SEM), fourier-transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC). Bioadhesive, sustained-release microcapsules were subsequently developed via an emulsification–solvent evaporation technique. Comprehensive characterization of the formulation was conducted, with key quality indices systematically evaluated. Notably, the formulation exhibited minimal leakage (0.07%) after 7 d of storage and retained 94.59% of its drug content over a 6-month period. Pharmacokinetic studies comparing the CT-Na active pharmaceutical ingredient (API) solution and the self-developed dry suspension revealed a marked extension in drug release for the latter. The dry suspension displayed a delayed Tmax (3 h vs. 2 h), an extended half-life (t1/2) (12.44 h vs. 4 h), and a moderately reduced peak concentration (Cmax) (3.99 μg/mL vs. 4.82 μg/mL), while achieving a significantly higher overall drug exposure (AUC0–24 h: 50.868 μg·h/mL vs. 30.281 μg·h/mL). These findings indicated that relative to the API solution, the optimized dry suspension provided sustained drug release with improved bioavailability.

Key words: Cefditoren, Ion-exchange resin, Sustained-release dry suspension

Supporting: